Search Results
Your search for ,maY matches 16890 pages
Showing 1451 - 1500Financial Hardships Caused by Cancer Are Long-Lasting for Many Working-Age Adults
Research shows that the average cost of medical care and drugs can top $42,000 in the first year following a cancer diagnosis, with the cost of some treatments, including chimeric antigen receptor T-cell therapies, exceeding $1 million. For many cancer survivors, these costs can have a lingering...
MRI-Guided Duration of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
In a Dutch phase II study (TRAIN-3) reported in The Lancet Oncology, Anna van der Voort, MD, and colleagues found that magnetic resonance imaging (MRI) detected complete radiologic response after only three cycles of neoadjuvant chemotherapy in many patients with stage II to III HER2-positive...
AUA, ASCO, and SUO Publish 2024 Amendment to Nonmetastatic Muscle-Invasive Bladder Cancer Guidelines
The American Urological Association (AUA), in partnership with ASCO and the Society of Urologic Oncology (SUO), has issued a 2024 clinical practice guideline amendment for the diagnosis and treatment of nonmetastatic muscle-invasive bladder cancer. The updated guidelines were published by...
Barriers to Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
Investigators have uncovered persistent racial and social disparities that may impede access to autologous hematopoietic cell transplantation for some patients with multiple myeloma, according to a recent study published by Esteghamat et al in Clinical Lymphoma, Myeloma & Leukemia. Background...
Combined ICI and VEGF Inhibitor Trials in Cancer: Cardiovascular Eligibility Criteria and Adverse Event Reporting
In a study reported in JACC:CardioOncology, Rankin et al analyzed the degree to which published phase II to IV trials of combination immune checkpoint inhibitor (ICI) and VEGF inhibitor treatment for cancer reported cardiovascular eligibility criteria and adverse events. As stated by the...
Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care
The current body of research may inadequately address the intersection of aging, health disparities, and cancer outcomes among older patients, according to a recent systematic review published by Gilmore et al in the Journal of the American Geriatrics Society. The findings revealed an urgent need...
Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being
Investigators have uncovered that the emotional and physical health of breast cancer survivors may be influenced by their relationship with their partners, according to a recent study published by Vachon et al in Healthcare. Background The diagnosis and treatment of breast cancer often place...
Rapid Guideline Update Supports Capivasertib for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer now have a new medication option that extends survival, according to an ASCO rapid guideline update.1 The update was designed to orient clinicians to outcomes from the CAPItello-291 trial, which led to the U.S. Food...
Expert Point of View: Glenn J. Hanna, MD
Glenn J. Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program), medical oncologist at the Center for Head & Neck Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School, Boston, was interviewed for his...
Can HPV Circulating Tumor DNA Guide Adjuvant Treatment of Oropharyngeal Cancer?
Although so-called liquid biopsies are now helping to determine the need for adjuvant therapy for a number of malignancies, oropharyngeal carcinoma is not yet one of them, according to a prospective pilot study from Memorial Sloan Kettering Cancer Center. The investigators evaluated the use of...
AI Analysis of Cell-Free DNA Fragments and Protein Biomarkers for Noninvasive Detection of Ovarian Cancer
A blood-based, machine learning assay that combines cell-free DNA (cfDNA) fragmentomes and protein biomarkers was able to differentiate patients with ovarian cancer from healthy controls at a high specificity of more than 99%, according to study results by Medina et al.1 It noninvasively recognized ...
Expert Point of View: Gini F. Fleming, MD
The session’s invited discussant at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer was Gini F. Fleming, MD, Professor of Medicine, and Medical Director of Gynecologic Oncology at the University of Chicago. She was elated with the findings of several studies showing...
Adagrasib Plus Cetuximab: Potential Option for KRAS G12C–Mutated Colorectal Cancer
Although KRAS was once considered an untargetable mutation, KRAS inhibitors are now approved for the treatment of KRAS-mutated non–small cell lung cancer (NSCLC) and are emerging as a potential option for the treatment of KRAS G12C–mutated colorectal cancer in combination with other therapies....
AI Model May Help Predict Treatment Responses, Select Most Effective Cancer Therapies in Patients With Cancer
Researchers have developed a novel artificial intelligence (AI) model that may accurately predict whether patients with cancer will respond to certain therapies, according to a recent study published by Sinha et al in Nature Cancer. The findings indicated that single-cell RNA sequencing data may be ...
Advanced-Stage Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following front-line therapy, key unmet clinical needs include reducing the relapse rate, decreasing acute and...
Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved
Recently, the U.S. Food and Drug Administration (FDA) approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy. Pegulicianine is a...
Potential Protective Effects of Aspirin Against Colorectal Cancer
Researchers may have uncovered how the long-term daily use of aspirin may help prevent the development and progression of colorectal cancer, according to a recent study published by De Simoni et al in Cancer. Study Methods and Results In the recent study, the researchers collected the tissue...
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the type II RAF inhibitor tovorafenib (Ojemda) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation. This...
Wendy Vogel, MSN, FNP, AOCNP, FAPO, on the Evolving Role of Advanced Practice Providers in Oncology Care
Wendy Vogel, MSN, FNP, AOCNP, FAPO, of the Advanced Practitioner Society for Hematology and Oncology, summarizes a panel discussion in which she took part, on forming interprofessional oncology care teams that include advanced practitioners. Such collaboration may improve patient outcomes and help...
Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Barker et al found that induction treatment with vismodegib followed by concurrent treatment with vismodegib and curative-intent radiation therapy showed efficacy in patients with locally advanced unresectable basal cell carcinoma. ...
FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
On April 22, the U.S. Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva) with bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. QUILT-3.032 Trial Efficacy...
Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis
Researchers have found that spatial tissue analysis may help predict early posttreatment relapse and illuminate new potential therapies in patients with high-grade serous ovarian carcinoma, according to a recent study published by Xu et al in Science Advances. Background Many patients with...
Chemohormonal Therapy for Locally Advanced Prostate Cancer
A neoadjuvant chemohormonal therapy combination may offer extended control of prostate-specific antigen (PSA) levels in patients with locally advanced prostate cancer compared with hormonal therapy alone, according to a recent study published by Qian et al in The Journal of Urology. Background...
Cabozantinib in Metastatic Pheochromocytomas or Paragangliomas
In the single-center phase II Natalie trial reported in The Lancet Oncology, Jimenez et al found that cabozantinib was active in patients with unresectable and progressive metastatic pheochromocytomas or paragangliomas (MPPGs). As stated by the investigators: “Up to 50% of MPPGs are associated with ...
Propofol-Based Anesthesia May Offer Improved Detection of Serrated Polyps During Colonoscopy
Deeper sedation with the anesthetic drug propofol may improve detection of serrated polyps in patients undergoing colonoscopy to screen for colorectal cancer, according to a recent study published by Quaye et al in Anesthesiology. Background Nearly all colorectal cancers start as polyps....
Observing a Healthy Diet May Reduce Risk of Cardiovascular Disease in Breast Cancer Survivors
Following a healthy diet may reduce the risk of cardiovascular disease in female breast cancer survivors, according to a recent study published by Ergas et al in JNCI Cancer Spectrum. Background Cardiovascular disease is one of the leading causes of non–breast cancer–related mortality among...
Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer
On April 18, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor alectinib (Alecensa) for adjuvant treatment after tumor resection in patients with ALK-positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test. Alectinib is an orally...
Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers
A novel MDM2 inhibitor has demonstrated antitumor activity in progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium. Results of the phase I/II trial showed an overall response rate of 13% and a...
Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer
A novel single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition method using lead (Pb)-212–prostate-specific membrane antigen (PSMA)-based targeted alpha therapy may provide convenient detection of radiopharmaceutical biodistribution and could lead to improved practice ...
Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC
The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, the Pulmonary Pathology Society, the Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations on the use of certain...
Improving Early Detection of Pancreatic Cancer in High-Risk Patients
Researchers have identified a novel strategy to screen for pancreatic cancer in high-risk patients, according to a recent study published by Zogopoulos et al in JNCCN–Journal of the National Comprehensive Cancer Network. The findings demonstrated the feasibility of improving the early detection and ...
Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities
Investigators have found a higher rate of mortality among patients with intellectual and developmental disabilities diagnosed with breast cancer, colorectal cancer, or lung cancer, according to a recent study published by Hansford et al in the Canadian Journal of Public Health. Study Methods and...
Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors
In a study reported in JAMA Oncology, Kristen D. Brantley, PhD, MPH, and colleagues identified the risk of a second primary breast cancer among survivors of breast cancer diagnosed at age 40 or younger, including among women with and without germline pathogenic variants. Study Details The study...
Metastatic Favorable-Risk RCC After Progression on VEGF/IO Therapy
This is Part 1 of Later-Line Considerations in Relapsed/Refractory Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rana McKay, Bradley McGregor, and Sumanta K. Pal discuss the management of metastatic...
Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma
Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma, according to a recent study published by Leonard-Murali et al in Nature Communications. The findings demonstrated the potential to...
The Lancet Commission on Breast Cancer: Reducing Overlooked Inequities in Breast Cancer
Investigators have uncovered persistent inequities in breast cancer that may systematically leave many patients behind in spite of recent improvements in research, treatment, and survival, according to a recent report from The Lancet Breast Cancer Commission. These findings were published by Coles...
A Pioneering Female Oncologist in Morocco Helps Advance the Global Shift Toward Gender Equity in Academia
Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation of researchers and practitioners and enrich global oncology. I recently had the privilege to speak with Ouissam Al Jarroudi, MD, about her...
Cabozantinib in Advanced Adrenocortical Carcinoma
In a single-center phase II trial reported in The Lancet Oncology, Campbell et al found that cabozantinib monotherapy showed activity in adult patients with advanced adrenocortical carcinoma. Study Details In the trial, 18 patients enrolled at The University of Texas MD Anderson Cancer Center...
New Findings Suggest No Correlation Between GLP-1 Receptor Agonists and Thyroid Cancer Risk
Glucagon-like peptide (GLP)-1 receptor agonists may not be associated with an increased risk of thyroid cancer, according to a recent study published by Pasternak et al in the BMJ. Background GLP-1 receptor agonists are designed to reduce blood sugar levels and appetite. They have become...
Study Identifies Genetic Variants Potentially Linked to Prevalent or Persistent HPV Infections
Investigators have uncovered genetic variants that may predispose certain female patients to prevalent or persistent human papillomavirus (HPV) infections and increase their risk of developing cervical cancer, according to a recent study published by Adebamowo et al in the European Journal of Human ...
Exploring Geriatric Assessment Effectiveness: Insights From the 2023 International Society of Geriatric Oncology Conference
Geriatric assessment has emerged as a pivotal tool in optimizing cancer care for older patients, aiming to mitigate treatment toxicity, enhance treatment adherence, and improve quality of life. The recommended areas for evaluation in a geriatric assessment focus on identifying health issues that...
Newly Diagnosed Locally Advanced HNSCC: Adding Pembrolizumab to Concurrent Chemoradiotherapy
As reported in The Lancet Oncology by Jean-Pascal Machiels, MD, and colleagues, the phase III KEYNOTE-412 trial showed no significant improvement in event-free survival with the addition of pembrolizumab to concurrent chemoradiotherapy in newly diagnosed patients with high-risk locally advanced...
Oxaliplatin-Based Adjuvant Therapy in Older Patients With Stage III Colon Cancer
In a pooled analysis of data from clinical trials in the ACCENT/IDEA databases reported in the Journal of Clinical Oncology, Claire Gallois, MD, and colleagues found that patients aged ≥ 70 years receiving oxaliplatin-based adjuvant chemotherapy for stage III colon cancer had a similar time to...
Breast Cancer With Sentinel Node Metastases: Axillary Dissection vs Sentinel Node Biopsy Alone
As reported in The New England Journal of Medicine by de Boniface et al, the phase III SENOMAC trial showed noninferiority in recurrence-free survival with sentinel node biopsy alone vs completion axillary node dissection in patients with breast cancer and sentinel node metastases. Study Details In ...
Illuminating a Potential Culprit in Melanoma Treatment Resistance
Researchers may have uncovered the mechanisms behind the development of targeted therapy resistance in melanoma, according to a recent study published by Aya Moreno et al in Cell Reports. Background The global incidence of melanoma—the deadliest type of skin cancer—is rising, making novel...
Radon Gas Exposure May Be Linked to Increased Incidence of Lung Cancer in Nonsmokers
Long-term exposure to radon gas may be associated with a rise in nonsmoking lung cancer cases, according to a recent consumer survey conducted on behalf of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James)....
Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer
Researchers have found that a novel urine biomarker test may effectively halve the number of cystoscopies necessary in high-risk patients with bladder cancer, according to recent findings presented by Dreyer et al at the European Association of Urology (EAU) Congress 2024. The research also...
Longer Interval May Be Safe for Prostate Cancer Screening in Low-Risk Patients
Undergoing a prostate-specific antigen (PSA) blood test every 5 years may be adequate for screening low-risk men for prostate cancer, according to recent findings presented by Albers et al at the European Association of Urology (EAU) Congress 2024 and simultaneously published in European Urology....
The Lancet Commission on Prostate Cancer: Strategies to Prepare for Predicted Increases in Disease Burden by 2040
Investigators have projected impending increases in the incidence and mortality rates of prostate cancer—especially among individuals in low- and middle-income countries—and proposed new strategies to improve screening, awareness, research diversification, and treatment in a recent The Lancet...
Blood-Based Machine-Learning Assay May Noninvasively Detect Early Ovarian Cancer
Ovarian cancer is the eighth most-common cancer among women globally, and the eighth most-common cause of death from cancer worldwide. In the United States alone, in 2023, there were nearly 20,000 new cases of the cancer, and about 13,270 deaths from the disease. Ovarian cancer is largely...
